Loading...

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Duvelisib (Copiktra(®)) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel)
Main Authors: Rodrigues, Daniel A., Sagrillo, Fernanda S., Fraga, Carlos A. M.
Format: Artigo
Language:Inglês
Published: MDPI 2019
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6631818/
https://ncbi.nlm.nih.gov/pubmed/31064155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph12020069
Tags: Add Tag
No Tags, Be the first to tag this record!